The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study
Table 3
Comparison of treated (taking antihypertensive medications) PWH and NHANES subjects.
(a)
Variable
NHANES
PWH
Median (IQR)
Median (IQR)
Systolic BP (mmHg)
127 (119–140)
539
134 (126–141)
118
<0.001
Diastolic BP (mmHg)
76 (67–83)
539
84 (76–89)
118
<0.001
BMI (kg/m2)
30.6 (27.3–35.0)
534
27.7 (24.8–31.0)
115
<0.001
Creatinine (mg/dL)
0.99 (0.86–1.12)
508
0.90 (0.80–1.10)
116
0.007
eGFR (mL/min/1.73 m2)
89 (73–101)
508
98 (74–108)
116
0.005
Cholesterol (total) (mg/dL)
186 (160–214)
509
164 (137–193)
85
<0.001
(b)
Variable
NHANES
PWH
(%)
(%)
HIV
Positive
2 (0.7)
33 (29.5)
<0.001
Negative
281 (99.3)
79 (70.5)
HCV
Positive
17 (13.4)
91 (81.3)
<0.001
Negative
491 (96.7)
21 (18.8)
Diabetes
Positive
178 (33.0)
31 (26.3)
0.188
Negative
361 (67.0)
87 (73.7)
Smoking
Current
109 (20.2)
16 (18.6)
0.166
Former
192 (35.6)
23 (26.7)
Never
238 (44.2)
47 (54.7)
NHANES indicates subjects from the National Health and Nutrition Examination Survey of the general United States population; PWH, patients with hemophilia; IQR, interquartile range; BP, blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; and HCV, hepatitis C virus.
